Chemical Information | |
Antiviral agent ID | DrugRepV_1656 | |
Antiviral agent name | Febuxostat | |
IUPAC Name | 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methyl-1,3-thiazole-5-carboxylic acid | |
SMILES (canonical) | CC1=C(SC(=N1)C2=CC(=C(C=C2)OCC(C)C)C#N)C(=O)O | |
Molecular Formula | C16H16N2O3S | |
Molecular Weight (g/mol) | 316.375 | |
InChl | InChI=1S/C16H16N2O3S/c1-9(2)8-21-13-5-4-11(6-12(13)7-17)15-18-10(3)14(22-15)16(19)20/h4-6,9H,8H2,1-3H3,(H,19,20) | |
Structural Information | |
|
|
Clinical Information | |
Category | Musculo-Skeletal System
| |
Primary Indication (Clinical trial phases) | Approved
| |
Biological Information | |
Primary Indication (Disease Category) | Non Infectious Disease
| |
Primary Indication (Disease) | Hyperuricemia
| |
Secondary Indication | Zika virus (ZIKV) NA MR766 | |
Secondary Indication (Approaches) | Experimental-HTS | |
Secondary Indication (Methods) | In-vitro | |
Secondary Indication (Model system) [cell lines/ animal models] | Astrocytes
| |
Secondary Indication (Mode of viral infection) | Adsorption
| |
Secondary Indication (Viral titer) | 1 MOI
| |
Secondary Indication (Mode of drug delivery) | Culture
| |
Secondary Indication (Cell based assay) | Cell viability assay
| |
Secondary Indication (Change) | No significant effect
| |
Secondary Indication (Type of Inhibition) | Percentage Inhibition [ 0 % ] | |
Reference | Xu M, Lee EM, Wen Z, Cheng Y, Huang WK, Qian X, Tcw J, Kouznetsova J, Ogden SC, Hammack C, Jacob F,.Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen.Nat Med. 2016 Oct;22(10):1101-1107. doi: 10.1038/nm.4184. Epub 2016 Aug 29. PMID:27571349
| |
Comment | The identified compounds that either inhibit ZIKV infection or suppress infection-induced caspase-3 activity in different neural cells
| |